Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

2 Apr 2015 16:55

RNS Number : 3808J
Epistem Holdings plc
02 April 2015
 



 

 

 

 

 

Epistem Holdings Plc ("Epistem" or the "Company")

 

Directors' Shareholdings

 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

 

As a result of the subscription for Partnership Shares and the award of Matching Shares, executive Directors, Matthew Walls, Dr Catherine Booth, John Rylands and Dr Allan Brown each increased their beneficial interests in the Company by 450 ordinary shares of 1.5p each. These shares were acquired on 28 January 2015, 27 February 2015 and 27 March 2015 at prices of 273p, 260p and 225p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

 

Ordinary Shares %

 

Matthew Walls 12,820 0.13%

Dr Catherine Booth 987,175 9.87%

John Rylands 197,073 1.97%

Dr Allan Brown 1,761 0.01%

 

Epistem further announces that it was informed on 2 April 2014 that, on that day, Dr Catherine Booth transferred 2,983 ordinary shares of 1.5 pence each to her Self Invested Personal Pension fund at a price of 225p Following this transaction, Dr. Catherine Booth's beneficial interest remains unchanged at 987,175 ordinary shares representing 9.87% of the Company's issued share capital.

 

 

 

For further details please contact:

 

Epistem Holdings Plc

Matthew Walls: Chief Executive Officer ++44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel ++44 (0)207 418 8900

Clare Terlouw

 

Walbrook PR

Mike Wort ++44 (0)207 933 8780

Anna Dunphy

 

Please see http://www.epistem.co.ukfor additional information.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUGDSDUGBGUD
Date   Source Headline
16th Jun 20232:28 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSMulti-partner grant awarded
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester
9th Feb 20232:05 pmRNSSecond Price Monitoring Extn
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSAIHL test preliminary recommendation by NICE
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 20234:40 pmRNSSecond Price Monitoring Extn
25th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20234:40 pmRNSSecond Price Monitoring Extn
19th Jan 20234:35 pmRNSPrice Monitoring Extension
29th Dec 20226:10 pmRNSResult of AGM
5th Dec 20227:00 amRNSNotice of AGM
30th Nov 20227:00 amRNSBlock Listing Six Monthly Return
21st Nov 20227:00 amRNSAudited Final Results
14th Nov 20227:00 amRNSNotice of Results
24th Oct 20227:00 amRNSGrant of options
5th Oct 20224:40 pmRNSSecond Price Monitoring Extn
5th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSUS FDA pre-submission for Genedrive MT-RNR1 kit
26th Sep 20227:00 amRNSNICE to accelerate evaluation of Genedrive test
22nd Aug 20227:00 amRNSNICE includes CYP2C19-ID Kit in new programme
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:00 pmRNSPrice Monitoring Extension
16th Jun 20227:00 amRNSNICE to evaluate the Genedrive® MT-RNR1 Test
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.